S&P Global set a GBX 1,500 ($19.54) price objective on GlaxoSmithKline plc (LON:GSK) in a research note issued to investors on Wednesday. The brokerage currently has a sell rating on the stock.

Several other equities analysts have also recently weighed in on GSK. BNP Paribas reaffirmed an underperform rating and issued a GBX 1,520 ($19.80) price target on shares of GlaxoSmithKline plc in a research report on Tuesday, March 28th. J P Morgan Chase & Co reaffirmed a neutral rating and issued a GBX 1,670 ($21.76) price target on shares of GlaxoSmithKline plc in a research report on Tuesday, March 28th. Kepler Capital Markets reaffirmed a reduce rating and issued a GBX 1,500 ($19.54) price target on shares of GlaxoSmithKline plc in a research report on Wednesday, March 29th. Shore Capital reaffirmed a hold rating on shares of GlaxoSmithKline plc in a research report on Thursday, March 30th. Finally, Liberum Capital reaffirmed a buy rating and issued a GBX 1,900 ($24.75) price target on shares of GlaxoSmithKline plc in a research report on Thursday, March 30th. Four investment analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have given a buy rating to the stock. GlaxoSmithKline plc presently has a consensus rating of Hold and a consensus price target of GBX 1,734.73 ($22.60).

GlaxoSmithKline plc (GSK) opened at 1518.50 on Wednesday. The firm’s 50-day moving average price is GBX 1,638.77 and its 200-day moving average price is GBX 1,627.17. GlaxoSmithKline plc has a 12 month low of GBX 1,446.50 and a 12 month high of GBX 1,745.56. The firm’s market cap is GBX 74.22 billion.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/glaxosmithkline-plc-longsk-given-a-gbx-1500-price-target-by-sp-global-analysts/1461915.html.

The business also recently declared a dividend, which will be paid on Thursday, October 12th. Stockholders of record on Thursday, August 10th will be paid a dividend of GBX 19 ($0.25) per share. The ex-dividend date is Thursday, August 10th. This represents a dividend yield of 1.23%.

In related news, insider Manvinder Singh Banga purchased 2,267 shares of the firm’s stock in a transaction dated Wednesday, July 26th. The stock was bought at an average price of GBX 1,599 ($20.83) per share, for a total transaction of £36,249.33 ($47,224.24). Also, insider Patrick Vallance purchased 861 shares of the firm’s stock in a transaction dated Friday, July 14th. The shares were bought at an average price of GBX 1,618 ($21.08) per share, with a total value of £13,930.98 ($18,148.75). In the last 90 days, insiders have bought 3,150 shares of company stock valued at $5,054,075.

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with Analyst Ratings Network's FREE daily email newsletter.